ClearPoint Neuro, Inc. (NASDAQ:CLPT)
| Market Cap | $221.49M-50.0% |
| Revenue (ttm) | $45.49M+32.5% |
| Net Income | -$36.13M-56.2% |
| EPS | -$1.21-44.0% |
| Shares Out | 32.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,108,673 |
| Open | $7.15 |
| Previous Close | $7.31 |
| Day's Range | $6.85 - $7.45 |
| 52-Week Range | $6.85 - $19.63 |
| Beta | 1.36 |
| Analysts | Buy |
| Price Target | $21.50(+211.14%) |
| Earnings Date | Mar 16, 2027 |
About CLPT
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating CLPT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 16, 2027Earnings report
$CLPT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CLPT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CLPT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CLPT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CLPT Revenue by Segment
| Neurosurgery navigation and therapy | $5.44M | 30.23% |
| Neurosurgery Navigation and Therapy - Disposable Products | $5.44M | 30.23% |
| Biologics and drug delivery | $4.89M | 27.21% |
| Capital equipment and software | $1.74M | 9.68% |
| Capital Equipment and Software - Services | $474.00K | 2.64% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CLPT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CLPT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CLPT
| VTIVanguard Morningstar Total Stock Market ETF | $7.18M |
| IWMiShares Russell 2000 ETF | $5.29M |
| VXFVanguard Extended Market ETF | $3.77M |
| IWOiShares Russell 2000 Growth ETF | $1.96M |
| VTWOVanguard Russell 2000 ETF | $1.77M |
| KOMPState Street SPDR S&P Kensho New Economies Composite ETF | $918.76K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CLPT’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| FDHT | FIDELITY DIGITAL HEALTH ETF | 1.26% |
| XHE | State Street SPDR S&P Health Care Equipment ETF | 0.61% |
| IBRN | iShares Neuroscience and Healthcare ETF | 0.37% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.34% |
| IWC | iShares Micro-Cap ETF | 0.06% |
| KOMP | State Street SPDR S&P Kensho New Economies Composite ETF | 0.05% |
| TMFX | Motley Fool Next Index ETF | 0.01% |
Weight is the stock’s share of each fund’s holdings.
